(S)-2,3,5,6-Tetrahydro-6-Phenylimidazo[2,1-B]Thiazoletriylium Phosphate

In glycine Schiff base alkylation campaigns targeting (S)-4-chlorophenylalanine — a building block for peptidomimetic drug candidates — the (S)-2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazoletriylium phosphate is charged directly into a degassed toluene/aqueous KOH (50 wt%) biphase at a catalyst loading of 2.0 mol% to 4.5 mol% relative to N-(diphenylmethylene)glycine tert-butyl ester. The reactor, typically an 800 L glass-lined vessel equipped with a retreat-curve impeller operated at 320 rpm, is maintained at −5 °C to +2 °C via jacket-controlled silicone oil circulation. Alkylating agent (4‑chlorobenzyl bromide, 1.15 eq) is dosed over 90 min using a peristaltic pump; exotherm excursions beyond +4 °C degrade enantiomeric excess from a baseline of 92–94% to below 84% within a single batch, as documented by in-process chiral HPLC sampling (Chiralpak IA, 250×4.6 mm, 5 µm, n‑hexane/isopropanol 90:10, 1.0 mL/min, 254 nm). After 14 h of agitation, the organic phase is separated through a Westfalia disk-stack centrifuge at 4,500×g, washed with deionized water (conductivity < 1.5 µS/cm) to remove residual base, and concentrated under vacuum (Buchi R-220 SD, 45 °C bath, 25 mbar) until a viscous amber oil is obtained. The crude imine is cleaved with aqueous citric acid (15 wt%, 2.5 volumes) at 40 °C for 3 h; the liberated amino acid is precipitated by adjusting pH to 5.8 with 10% NaOH and collected on a Nutsche filter, washed with cold isopropanol, and dried in a conical vacuum dryer at 60 °C and 10 mbar. Typical isolated yields exceed 87% with chemical purity 99.2% (HPLC area %, Inertsil ODS-3, gradient MeCN/0.1% H₃PO₄). Enantiopurity is confirmed at 99.0% ee by derivatization with Marfey’s reagent and UPLC-MS. Compliance with ICH Q3C residual solvent limits is met through headspace GC-MS verification (Agilent 7697A/7890B); palladium and nickel content is monitored via ICP-MS (Agilent 7800) to remain below 10 ppm each, per EMA guideline EMEA/CHMP/SWP/4446/2000. The aqueous phase containing the catalyst is acidified with phosphoric acid to pH 2.8 and extracted with dichloromethane; recovered catalyst purity, assayed by ion-pair chromatography, typically falls to 92–95% after three recycles due to gradual Hofmann elimination by-products, which eventually necessitate a flash chromatography purification step (silica gel, MeCN/H₂O 8:2 containing 0.1% H₃PO₄) to restore enantioselectivity to >90% ee. Plant operators record batch-to-batch ee variability of ±1.6% when relative humidity in the charging area exceeds 65%, traced to partial hydration of the phosphate anion that alters the interfacial ion-pair geometry; pre‑drying of toluene over 4 Å molecular sieves to a water content of < 80 ppm (Karl Fischer titration) is mandatory under such conditions.

What Process Intensification Metrics Justify Imidazothiazolium Phosphate Over Conventional Cinchona Alkaloid Catalysts?

Continuous-flow asymmetric benzylation of a glycine Schiff base has been validated on a Corning Advanced-Flow G1 reactor with a 10 mL glass fluidic module, where the chiral phosphate catalyst, dissolved in toluene, is combined in a T-mixer with pre-cooled aqueous KOH and alkyl halide feed streams. Residence time is fixed at 12 min at 0 °C under 3 bar backpressure, yielding 93% ee and 96% conversion, monitored inline by a Mettler Toledo ReactIR 15 with a diamond ATR probe tracking the imine C=N stretch at 1626 cm⁻¹. Compared to a cinchonidinium bromide benchmark operated under identical conditions, the imidazothiazolium phosphate exhibits a turnover frequency of 8.4 h⁻¹ versus 5.1 h⁻¹, attributed to the rigid tricyclic scaffold that restricts C—N bond rotation and minimizes non-productive conformers. The volumetric productivity reaches 0.38 kg of (S)-tert-butyl-2-amino-3-(4-chlorophenyl)propanoate per liter of reactor volume per day, sufficient for early-phase clinical supply. Pressure-drop fouling is absent over 72 h of uninterrupted operation; however, trace solid K₂CO₃ formed when CO₂ ingress occurs must be captured on a 5 µm inline sintered-metal filter, which requires backflushing every 8 h with dry THF to maintain a differential pressure below 0.2 bar. The catalyst inventory in the organic loop is monitored by a Knauer UV photometer at 268 nm (π–π* transition of the phenyl substituent). Loss of catalyst into the aqueous phase, measured by ICP-OES phosphorus analysis, averages 1.8% per pass; a downstream counter-current extraction stage using methyl isobutyl ketone recovers 91% of that loss. The recovered material is redried azeotropically and re‑dissolved to the target 0.15 M concentration. The process has been filed as a Drug Master File type II section under 21 CFR 314.420, with residual phosphate specification set at < 50 ppm in the final API. Toxicological qualification of the catalyst impurity follows ICH M7 option 4 control, with a permitted daily exposure of 15 µg/day based on bacterial reverse mutation assay (Ames test, OECD TG 471) results that indicated non-mutagenicity up to 5,000 µg/plate. Wastewater from aqueous phase neutralization is stripped with activated carbon (Norit SX Plus, 0.5 wt%) to adsorb dissolved aromatic species before discharge, meeting local COD limits of < 500 mg/L.

Deprotonation of the imidazothiazolium cation with potassium tert-butoxide in anhydrous THF generates a nucleophilic chiral N-heterocyclic carbene that coordinates copper(I) chloride, forming an air-sensitive, pale-yellow powder after filtration through Celite and precipitation with cold pentane. This precatalyst, when applied at 1.8 mol% to 1,4‑addition of diethylzinc to 2‑cyclohexen‑1‑one in toluene/TBME (1:1) at −30 °C, gives (R)-3‑ethylcyclohexanone with 89% ee and 95% isolated yield after distillation over a 20 cm Vigreux column at 72–74 °C/10 mbar. The active copper-carbene complex has been characterized by ESI-MS (m/z 386.1 [M⁺]) and its purity confirmed by elemental analysis (C, H, N, S within ±0.2% of theoretical). Rigorous exclusion of moisture and oxygen is enforced: solvents are dried over Na/benzophenone and degassed by freeze-pump-thaw cycles, and all manipulations are performed in an MBraun LabMaster SP glovebox with < 0.1 ppm O₂ and < 0.5 ppm H₂O. Scale‑up to multigram substrate quantities in a jacketed 500 mL Schlenk flask maintained under argon results in an induction period of 8–12 min, after which an exotherm of 6–8 °C is controlled by adjusting cryostat setpoint. Quenching with saturated NH₄Cl, followed by phase separation and aqueous extraction with three 100 mL portions of tert‑butyl methyl ether, yields product of sufficient purity for subsequent steps without chromatography. The phosphate salt can be regenerated from the aqueous phase after protonation with dilute HCl, re-extracted into dichloromethane, and recrystallized from ethanol/diethyl ether to restore >98% chemical purity (HPLC). The chiral ketone serves as a key intermediate in the synthesis of (R)-baclofen, with the stereochemical outcome confirmed by comparison of optical rotation to a standard ([α]D²⁵ = −3.2°, c 1, CHCl₃) and derivatization to the known amide. Compliance documentation for this lab-scale methodology references ASTM E2018-15 for property condition assessment of equipment integrity, and all weighing is performed on a Mettler Toledo XPR205 balance calibrated daily with certified OIML class E2 weights.

Brush-Type Chiral Stationary Phases Engineered from Optically Pure Cationic Monomers

Grafting of (S)-2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazoletriylium phosphate onto 5 µm Kromasil silica (100 Å, surface area 310 m²/g) proceeds via a thiol‑ene reaction: the silica is first silanized with (3‑mercaptopropyl)trimethoxysilane in refluxing toluene (110 °C, 24 h) under nitrogen, adding pyridine as acid scavenger. Elemental analysis determines sulphur incorporation of 0.42 mmol/g (LECO SC832 analyser). The terminal thiol is then coupled to the vinyl‑functionalized imidazothiazolium salt — synthesized separately from the (S)-phenylglycinol-derived precursor and vinylbenzyl chloride — in the presence of AIBN (2 mol%) in degassed ethanol/water (4:1) at 65 °C for 18 h. The resulting chiral stationary phase (CSP) is endcapped with hexamethyldisilazane and slurry-packed into a 250×4.6 mm stainless steel column under 550 bar using a Haskel pneumatic pump. Column performance is evaluated according to USP <621> chromatography, with reduced plate height (h) of 2.8 for acenaphthene at an optimal flow of 0.55 mL/min (MeCN/water 60:40, 25 °C). The CSP resolves racemic 1,1′‑bi‑2‑naphthol (binaphthol) in normal-phase mode (hexane/2‑propanol 90:10) with a separation factor α of 2.31 and resolution Rs of 4.8, and separates the enantiomers of pindolol in reversed-phase mode (phosphate buffer pH 7.0/MeCN 70:30) with α = 1.62, Rs = 3.1. Long‑term stability testing under a continuous flow of mobile phase at 0.3 mL/min and 40 °C shows a retention drift of less than 2.6% over 1,200 column volumes; column bleed, measured by evaporative light-scattering detector gain comparison with a blank column, remains below 0.15 mV. This CSP format meets the criteria described in the FDA guidance for analytical procedures and methods validation (ICH Q2(R1)), with LOD and LOQ for the second-eluting enantiomer of binaphthol determined at 0.08 µg/mL and 0.24 µg/mL, respectively (signal‑to‑noise ratio of 3 and 10). For compliance with REACH Annex XVII, leaching tests (methanol/water 50:50 at 50 °C for 72 h) are performed and analysed by LC‑MS/MS; the concentration of liberated phosphate anion is below 0.02 ppm, confirming covalent bonding integrity. Storage conditions are specified at 2–8 °C in capped columns, and evidence of silanol activity after accelerated aging (pH 2.0 and pH 9.0 mobile phases for 500 column volumes) is negligible as tested with the Engelhardt test mixture.

For the asymmetric epoxidation of α,β-unsaturated ketones under alkaline biphasic conditions, the phosphate salt serves as a precatalyst that generates the active chiral ylide in situ. A typical procedure charges (S)-imidazothiazolium phosphate (5.0 mol%) and 2‑chloro‑2,5‑dimethylhexan‑3‑one (1.2 eq) in toluene, followed by 30% aqueous hydrogen peroxide (2.0 eq) and NaOH (1.5 eq as 20% solution) at 0 °C. The biphasic mixture is stirred with a Teflon‑coated magnetic bar at 1,200 rpm in a double‑walled reactor connected to a Julabo F32‑MH cryostat. Exotic polymeric surfactant (Triton X‑100, 0.3 mol%) is added to reduce interfacial tension and ensure a milky dispersion. Consumption of the enone is tracked by TLC (silica, hexane/ethyl acetate 4:1) and complete after 6 h. The organic layer is washed with saturated Na₂S₂O₃ to quench residual peroxide, dried over Na₂SO₄, and concentrated; flash chromatography (hexane/ethyl acetate 95:5) yields the oxirane as a colourless oil. For (E)-chalcone epoxidation, isolated yield reaches 84% with 90% ee, determined by HPLC on the above-described imidazothiazolium CSP (trans‑stilbene oxide isomers, α = 1.95). The catalyst is partially recovered by acidifying the aqueous phase with 10% HCl to pH 3, extracting with ethyl acetate, and removing peroxides with ferrous sulfate wash. Regenerated catalyst purity drops by approximately 4% per run, attributable to oxidative degradation of the thiazole sulfur; addition of 0.1 wt% butylated hydroxytoluene to the organic phase extends catalyst half‑life. The epoxide product finds downstream use in the manufacture of (S)-methoxyphenamine, a bronchodilator, through regioselective azide opening and Staudinger reduction, with the final API subjected to USP monograph testing for chromatography purity and specific rotation. Batch records for kilogram‑scale demonstration at a CRO facility standardize the workup pH to 6.9–7.1 to avoid epoxide hydrolysis, using an SI Analytics TitroLine 7800 autotitrator linked to a dosing pump.

When Diastereomeric Salt Resolution Outperforms Simulated Moving Bed Chromatography

Direct resolution of racemic 2‑(4‑isobutylphenyl)propanoic acid (ibuprofen) is achieved by combining 1.0 eq of the racemate with 0.52 eq of (S)-2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazoletriylium phosphate in a mixed solvent system of 85% 2‑propanol/water. The solution is heated to 65 °C until fully dissolved, then linearly cooled at 0.15 °C/min to −5 °C using a Lauda Proline RP 855 thermostat. The less soluble (S)-acid·(S)-ammonium diastereomeric salt crystallizes as fine white needles that are isolated on a centrifuge filter, washed with cold −10 °C 2‑propanol, and dried under vacuum (30 °C, 15 mbar). The liberated (S)-ibuprofen, after acidification with 2 N HCl and n‑heptane extraction, exhibits 99.1% ee (Chiralpak AD‑H, hexane/TFA/2‑propanol 98:0.1:2). Mother liquor enrichment with racemic material and controlled co‑cooling allows a cyclic resolution process yielding >92% theoretical recovery, documented in campaigns governed by cGMP for chiral intermediates (ICH Q7). Compared to simulated moving bed separation (SMB), this resolution requires a capital investment of approximately 40% less and has been implemented in a multipurpose 630 L Hastelloy C‑22 crystallizer equipped with a retreat‑curve impeller and wall‑scraping wiper. The chemical compatibility of the phosphate salt with stainless‑steel components is confirmed by immersion testing per ASTM G31-72, showing a corrosion rate of < 0.02 mm/year in the solvent matrix at process temperature. Regeneration of the resolving agent involves stripping the mother liquor of organics by vacuum distillation, extracting the residual ammonium salt with methylene chloride after basification to pH 10 with NaOH, and recrystallizing from ethanol/diethyl ether to a chemical purity of 99.6% (RP-HPLC). Residual solvent levels (ethanol < 5,000 ppm, ether < 50 ppm) comply with USP <467> class 3 solvents. This approach is economically preferred over SMB when the target throughput does not exceed 3.5 kg of resolved acid per batch, above which SMB’s continuous nature offers lower variable cost. The (S)-ibuprofen downstream is further esterified to the sodium salt and formulated into over-the-counter analgesics meeting USP 40 monographs for content uniformity (limit 85.0–115.0%) and dissolution (≥75% within 45 min, as per test <711>).

Electrochemical generation of chiral microenvironment in an ionic liquid electrolyte is realized by blending the imidazothiazolium phosphate at a concentration of 0.15 M with 0.85 M lithium bis(trifluoromethanesulfonyl)imide in propylene carbonate/ethylene carbonate (50:50 vol%), yielding a non-flammable liquid with viscosity of 38 cP at 25 °C (Brookfield DV‑II+ Pro, spindle SC4‑18). The electrolyte is applied in an undivided flow cell (MicroFlowCell, C‑Flow 5×5 mm graphite electrodes, gap 1 mm) for the enantioselective reduction of prochiral 2‑methyl‑3‑(4‑cyanophenyl)acrylate. A constant current density of 5 mA/cm² delivers complete conversion (>99% by GC) with 78% ee toward the (S)-ester, measured after quenching with ammonium chloride solution and extractive workup. The chiral ionic liquid serves simultaneously as solvent, supporting electrolyte, and stereochemical inductor, eliminating the need for a separate chiral auxiliary. Over 50 charge‑discharge cycles, the phosphate cation does not electrochemically decompose, as evidenced by ¹H and ¹³C NMR spectra remaining identical to the pristine material, and the fluoride content measured by ion chromatography (ICS‑6000) stays below 2 ppm, indicating no PF₆ hydrolysis. Conductivity, monitored by a Mettler Toledo SevenExcellence meter with InLab 710 platinum probe, shows a minor drift of 0.8% after 200 hours. Post‑electrolysis recovery of the ionic liquid is performed by diluting the catholyte with diethyl ether, filtering precipitated lithium salts, and passing the filtrate through a silica plug to remove neutral by‑products; the phosphate is then concentrated on a rotary evaporator and dried for 48 h under high vacuum (10⁻³ mbar) at 40 °C. Recycled material retains 97% of its original chiral induction capability over three re‑uses. For industrial compliance, the non‑halogenated phosphate anion avoids corrosive HF generation under cell abuse conditions, a criterion tested per UL 1642 nail penetration surrogate using a thermal ramp to 300 °C with on‑line TGA‑MS (Netzsch STA 449 F3 Jupiter) confirming only CO₂, H₂O, and P₂O₅ evolution. The abovementioned ester product is a precursor to the optically active building block (S)-3‑(4‑cyanophenyl)‑2‑methylpropanoic acid, used in PDE4 inhibitor synthesis, and complies with a chiral purity specification of >97% ee by the validated HPLC method as per ICH Q2(R1).